中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
Evaluation and Analysis of Drug-Use in Hospitals of China
2015年
10期
1304-1305,1306
,共3页
阿米娜·马木提%衣米提·阿不都拉
阿米娜·馬木提%衣米提·阿不都拉
아미나·마목제%의미제·아불도랍
脑蛋白水解物%单唾液酸四己糖神经节苷脂%帕金森病
腦蛋白水解物%單唾液痠四己糖神經節苷脂%帕金森病
뇌단백수해물%단타액산사기당신경절감지%파금삼병
Cerebroprotein hydrolysate%Sodium monosialotetrahexosylganglioside injection%Parkinson's disease
目的：探讨单唾液酸四已糖神经节苷脂钠联合脑蛋白水解物治疗帕金森病的临床疗效。方法：选取新疆和田人民医院收治的140例帕金森病患者作为研究对象，根据入院先后顺序分为观察组和对照组各70例，对照组患者采用单唾液酸四已糖神经节苷脂钠，观察组患者在对照组治疗的基础上加用脑蛋白水解物，观察2组患者的临床疗效及不良反应。结果：治疗后，2组患者的统一帕金森总评分较治疗前显著降低，且观察组患者的总评分显著低于对照组，差异有统计学意义（ P＜0.05）；观察组患者总有效率为82.86％（58／70），明显高于对照组的68.57％（48／70），差异有统计学意义（P＜0.05）；观察组患者的震颤、僵直、反射障碍主要症状平均消除时间为（15.3±2.3）周，对照组为（18.2±3.6）周，2组的差异有统计学意义（P＜0.05）；2组患者均未见明显不良反应。结论：单唾液酸四己糖神经节苷脂钠联合脑蛋白水解物治疗帕金森病，能有效改善临床症状，提高治疗效果，且无明显不良反应，值得推广。
目的：探討單唾液痠四已糖神經節苷脂鈉聯閤腦蛋白水解物治療帕金森病的臨床療效。方法：選取新疆和田人民醫院收治的140例帕金森病患者作為研究對象，根據入院先後順序分為觀察組和對照組各70例，對照組患者採用單唾液痠四已糖神經節苷脂鈉，觀察組患者在對照組治療的基礎上加用腦蛋白水解物，觀察2組患者的臨床療效及不良反應。結果：治療後，2組患者的統一帕金森總評分較治療前顯著降低，且觀察組患者的總評分顯著低于對照組，差異有統計學意義（ P＜0.05）；觀察組患者總有效率為82.86％（58／70），明顯高于對照組的68.57％（48／70），差異有統計學意義（P＜0.05）；觀察組患者的震顫、僵直、反射障礙主要癥狀平均消除時間為（15.3±2.3）週，對照組為（18.2±3.6）週，2組的差異有統計學意義（P＜0.05）；2組患者均未見明顯不良反應。結論：單唾液痠四己糖神經節苷脂鈉聯閤腦蛋白水解物治療帕金森病，能有效改善臨床癥狀，提高治療效果，且無明顯不良反應，值得推廣。
목적：탐토단타액산사이당신경절감지납연합뇌단백수해물치료파금삼병적림상료효。방법：선취신강화전인민의원수치적140례파금삼병환자작위연구대상，근거입원선후순서분위관찰조화대조조각70례，대조조환자채용단타액산사이당신경절감지납，관찰조환자재대조조치료적기출상가용뇌단백수해물，관찰2조환자적림상료효급불량반응。결과：치료후，2조환자적통일파금삼총평분교치료전현저강저，차관찰조환자적총평분현저저우대조조，차이유통계학의의（ P＜0.05）；관찰조환자총유효솔위82.86％（58／70），명현고우대조조적68.57％（48／70），차이유통계학의의（P＜0.05）；관찰조환자적진전、강직、반사장애주요증상평균소제시간위（15.3±2.3）주，대조조위（18.2±3.6）주，2조적차이유통계학의의（P＜0.05）；2조환자균미견명현불량반응。결론：단타액산사기당신경절감지납연합뇌단백수해물치료파금삼병，능유효개선림상증상，제고치료효과，차무명현불량반응，치득추엄。
OBJECTIVE: To investigate the clinical efficacy of sodium monosialotetrahexosylganglioside injection combined with cerebroprotein hydrolysate in treatment of parkinson's disease.METHODS:140 cases of patients with parkinson's disease in People's Hospital of Xinjiang Hetianwere selected to be divided into study group and control group via the order of admission, with 70 cases in each group. The control group were treated with sodium monosialotetrahexosylganglioside injection, the study group additionally received cerebroprotein hydrolysate based on the control group;the clinic efficacy and adverse reactions were observed in two groups.RESULTS:After treatment, UPDRS total score of the patients in two groups were significantly decreased compared with before treatment, and UPDRS score in study group was significantly lower than that in control group, with statistically significant difference ( P <0.05 ) .The total effective rate of study group was [ 82.86%( 58/70 ) ] higher than that of control group [68.57%(48/70)], the difference was statistically significant(P<0.05).The average disappearance time of main symptoms in terms of tremor, spasticity and reflecting barrier in study group were(15.3 ±2.3) weeks, and in control group were ( 18.2 ±3.6 ) weeks, there was statistically significant difference between two groups ( P <0.05 ) . CONCLUSIONS: Sodium monosialotetrahexosylganglioside injection combined with cerebroprotein hydrolysate in treatment of parkinson's disease can effectively improve the clinical symptoms, enhance the therapeutic effect with no obvious adverse reactions, which is worthy of promotion.
